Cel Sci (CVM) Net Margin (2010 - 2017)
Cel Sci (CVM) posted Net Margin of 25671.76% for Q2 2017, down 764.07% sequentially from 2971.04% in Q2 2016, and down 2270073.0% YoY from N/an in Q2 2016.
Cel Sci (CVM) Net Margin (2010 - 2017) Analysis & Trends
Cel Sci has reported Net Margin for 4 years, with the latest figure at 25671.76% in Q2 2017.
- Quarterly Net Margin fell 2270073.0% year-over-year to 25671.76% in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 2644.97% (up 115692.0% YoY) and the FY2011 annual result came in at 2800.88%, down 863974.0% from the prior year.
- Net Margin declined to 25671.76% in Q2 2017 per CVM's latest filing, from 2971.04% in the prior quarter.
- Over five years, Net Margin peaked at 2971.04% in Q2 2016 and troughed at 25671.76% in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -25,671.76% |
| Jun 30, 2016 | -2,971.04% |
| Sep 30, 2011 | -1,346.48% |
| Jun 30, 2011 | -4,023.43% |
| Sep 30, 2010 | -4,847.00% |